Fresenius Medical Care (FMS), a leading dialysis services provider, is experiencing profitability recovery due to cost savings from its FME25+ program. The company benefits from stable, recurring demand and regulated pricing in the dialysis market. Despite improving margins and closing the valuation gap with competitor DaVita, FMS trades at historically low valuations. It offers attractive returns to shareholders through high free cash flow, dividends, and significant share buybacks, making it a compelling defensive investment in healthcare services.
A former Meta engineer highlights two critical risks to Bitcoin: the threat of quantum computing breaking wallet security and the declining miner incentives as block rewards shrink. Quantum computing could eventually compromise Bitcoin's cryptography...
Empery sold 1,400 Bitcoin between May and July for about $87.1 million, using the proceeds to repay debt, finance acquisitions, cover legal costs, and support operations. The company now holds 1,514 Bitcoin and $73.9 million in cash. This marks a shi...
Intel has received 32 upward revisions for both earnings per share (EPS) and revenue estimates, with no downgrades, indicating strong market confidence. Analysts project Intel's EPS to grow from $1.09 in 2026 to $12.29 by 2035, and revenue to surpass...
A former Google and Meta software engineer has liquidated his entire Bitcoin portfolio after significant losses and a decline in institutional interest over three quarters. He attributes Bitcoin's recent price drop, over 35% in months, to a shift in ...
The iShares U.S. Insurance ETF (IAK) has earned a Very Attractive rating due to its focus on profitable and undervalued insurance stocks. Its holdings achieve an 18% return on invested capital (ROIC), a 4% free cash flow yield, and a low price-to-emb...
